MedPage Today19 小时
Broadly Neutralizing Antibodies Delayed Rebound in HIV Patients Who Stopped ART
SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year ...
Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...